Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of CX157 (TriRima) for the Treatment of Depression (CX157-200)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
CeNeRx BioPharma Inc.
ClinicalTrials.gov Identifier:
NCT00739908
First received: August 20, 2008
Last updated: June 26, 2012
Last verified: June 2012

August 20, 2008
June 26, 2012
September 2008
July 2009   (final data collection date for primary outcome measure)
Change From Randomization in Montgomery and Asberg Depression Rating Scale (MADRS) [ Time Frame: Randomization and study end (Week 6). ] [ Designated as safety issue: No ]
The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item checklist designed to measure the overall severity of depressive symptoms in patients with MDD [Montgomery, 1979]. Items are rated on a scale of 0-6, with scores ranging from 0 to 60 with 0 being symptom free and 60 being the most severe depression. MADRS was assessed at randomization and Weeks 1, 2, 4 and 6 of the study.
The primary efficacy measure is the Montgomery-Asberg Depression Rating Scale (MADRS). [ Time Frame: Weekly and bi-weekly assessments ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00739908 on ClinicalTrials.gov Archive Site
  • Montgomery and Asberg Depression Rating Scale (MADRS) Response Rate [ Time Frame: Week 6 or the last available post treatment result (LOCF) ] [ Designated as safety issue: No ]
    MADRS is a 10-item checklist designed to measure the overall severity of depressive symptoms in patients with MDD [Montgomery, 1979]. Items are rated on a scale of 0-6, with scores ranging from 0 to 60 with 0 being symptom free and 60 being the most severe depression. Percentage of participants who achieved a reduction in total MADRS score of at least 50% or more as compared to baseline. MADRS was assessed at randomization and Weeks 1, 2, 4, and 6 of the study. MADRS Responder rate at Week 6 or the last available post treatment result (LOCF) is reported here.
  • Montgomery and Asberg Depression Rating Scale (MADRS) Remitter Rate [ Time Frame: Week 6 or the last available post treatment result (LOCF) ] [ Designated as safety issue: No ]
    Percentage of participants with total MADRS score of 11 or less. MADRS was assessed at randomization and Weeks 1, 2, 4, and 6 of the study. MADRS Remitter rate at Week 6 or the last available post treatment result (LOCF)is reported here.
  • The Hospital Anxiety and Depression Scale (HADS) [ Time Frame: Randomization and Week 6 or the last available post treatment result (LOCF) ] [ Designated as safety issue: No ]
    HADS is a subject-rated questionnaire designed to detect states of anxiety and depression. The HADS consists of 14 questions relating to anxiety or depression, each with a choice of four responses [Zigmond, 1983]. These responses are numerically scored 0-3, with 0 representing the least severe response and 3 representing the most severe response. The highest possible total score is 42. HADS was assessed at randomization and Weeks 1, 2, 4, and 6 of the study. Change from randomization in the HADS total score at Week 6 or the last available post treatment result (LOCF) is reported here.
  • Inventory of Depressive Symptomatology 30 Item -Self Report (IDS -SR 30 Items) [ Time Frame: Randomization and Week 6 or the last available post treatment result (LOCF) ] [ Designated as safety issue: No ]
    IDSR-SR 30 measures the severity of depressive symptoms by subjects. This scale has 30 items. The minimum score is 0 and the maximum possible IDS-30 score is 90 (the highest severity). IDS-SR30 was administered at screening, randomization and Weeks 1, 2, 4, and 6. Change from randomization in the IDS-SR30 total score at Week 6 or the last available post treatment result (LOCF) is reported here.
  • Clinical Global Impression - Improvement of Illness (CGI-I) [ Time Frame: Week 6 or the last available post treatment result (LOCF) ] [ Designated as safety issue: No ]
    The Clinical Global Impression - Improvement of Illness (CGI-I) was rated on a 7-point scale by the investigator to measure subject's total improvement compared to his/her condition at randomization according to the following scale: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. CGI-I was measured at Weeks 1, 2, 4 and 6. Percentage of participants "very much improved" and "much improved" at Week 6 or the last available post treatment result (LOCF) is reported here.
  • Clinical Global Impression - Severity of Illness (CGI-S) [ Time Frame: Week 6 or the last available post treatment result (LOCF) ] [ Designated as safety issue: No ]
    CGI-S measures the study rater's assessment of the severity of depression illness. CGI-S is rated on a scale of 1-7 as follows: 0 = not assessed, 1 = normal, not at all ill, 2 = borderline mentally ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, and 7 = among the most extremely ill patients. CGI-S was measured at randomization and Weeks 1, 2, 4 and 6. Percentage of subjects reported as normal, not at all ill; borderline mentally ill; and mildly ill is reported here at Week 6 or the last available post treatment result (LOCF).
Safety measures: PE, clinical laboratory evaluations, 12-lead ECG, AEs, vital signs, and suicidality assessment using the Columbia Suicide Severity Rating Scale (C-SSRS). [ Time Frame: Weekly and bi-weekly assessments ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
A Study of CX157 (TriRima) for the Treatment of Depression
A Randomized, Double-Blind, Placebo-Controlled Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 (TriRima) 60mg Three Times a Day (TID) in Subjects With Major Depressive Disorder

The purpose of this study is to examine the efficacy of CX157 60 mg administered three times a day (180 mg daily dose) as compared to placebo in subjects with Major Depressive Disorder (MDD). Secondary objectives are to evaluate the safety and tolerability and steady state pharmacokinetic profile of CX157 in these subjects.

This is a Phase II, randomized, double-blind, placebo-controlled, parallel-group, multi-center study comparing the efficacy, safety and tolerability of CX157 60mg TID and placebo. This study will be conducted at approximately 12 investigative sites in the US.

Subjects with suspected Major Depressive Disorder (MDD) and experiencing a Major Depressive Episode (MDE) who the investigator wishes to consider for enrollment in the study and who provide written informed consent will initially be evaluated by the Inventory of Depressive Symptomatology 30 item -Self Report (IDS-SR30) administered via Interactive Voice Response System (IVRS). Subjects who meet the minimum score of 40 on the IDS-SR30 will proceed with the remaining study related assessments at the Screening visit. Those subjects who meet all inclusion criteria and none of the exclusion criteria will enter a one to two week Screening period to confirm eligibility and to capture Screening data prior to Randomization. At the Randomization visit, all eligibility requirements will be reconfirmed. The subjects who meet all criteria will be randomized to study medication and enter into a six-week treatment period and a subsequent one week Follow-Up period. The total duration of participation for subjects who complete all phases of the study will be approximately 8-9 weeks. During the treatment period, clinic visits will occur at Week 1, Week 2, Week 4, and Week 6. A subsequent clinic visit will occur at the end of the one week Follow-Up period. The clinical site will contact the subjects via telephone at Weeks 3 and 5 to inquire about their wellbeing, query about adverse events and administer the suicidality scale.

Eligible subjects will be randomized (1:1) to receive:

  • CX157 60mg three times a day (TID) for a total daily dose of 180 mg, or
  • Placebo administered three times a day.

Subjects who discontinue from the study for any reason will not be replaced.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Major Depressive Disorder
  • Drug: CX157 (TriRima)
    Six capsules administered three times a day for six weeks.
    Other Name: CX157 (TriRima)
  • Drug: Placebo
    Six capsules administered three times a day for six weeks.
    Other Name: Sugar Pill
  • Experimental: CX157 (TriRima)
    Intervention: Drug: CX157 (TriRima)
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
285
July 2009
July 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female = 18 years of age and <60 years
  • Able to read, understand, converse in English
  • Willing to comply with diet restrictions, concomitant medication restrictions, & all study requirements
  • Good general health as ascertained by:Medical history, Physical exam, Supine & standing vital signs, Clinical lab evaluations, 12-lead Electrocardiogram (ECG)
  • Diagnosis of MDD;
  • A total score =>40 on the IDS-SR30 assessed via IVRS at Screening and Randomization

Exclusion Criteria:

  • Subject's current MDD episode is >2 years
  • History of Substance Use Disorder at Screening or 12 months prior (except for nicotine)
  • Current diagnosis of Obsessive-Compulsive Disorder;

    • Panic Disorder or Post-Traumatic Stress Disorder;
    • Anorexia nervosa, Bulimia nervosa, or eating disorder not otherwise specified;
    • Any Axis I Disorder clinically predominant to their MDD (within 6 mo);
    • Presence of psychotic features with current depressive episode;
    • Antisocial or Borderline Personality Disorder
  • At risk for suicide
  • Lack of response to >2 trials of adequate dose & duration of antidepressants of different mechanistic classes
  • Electroconvulsive therapy within 1 year of Screening
  • Subject has taken any psychoactive drug within 2 weeks of Randomization
  • History of cardiac abnormalities including abnormal vital sign measurements
  • Clinically significant abnormal ECG at Screening
  • History within past 2 years of: Significant head trauma;

    • Surgical procedure involving brain or meninges; Encephalitis or meningitis;
    • Degenerative CNS disorder (Alzheimer's or Parkinson's);
    • Epilepsy;
    • Mental retardation
  • Clinically significant Liver Function Test (LFT) and other lab abnormalities
  • A history of hypothyroidism and treatment with a stable dosage of thyroid replacement medication for <6 months prior to Screening
  • A history of hyperthyroidism treated (medically or surgically) <6 months prior to Screening
  • Participation in a clinical investigation of a psychotropic drug within 90 days prior to Screening OR used any other investigational drug within 60 days prior to Screening
  • Presence of any medical history which includes:

    • Hypersensitivity to CX157 or excipients, other MAO inhibitors, or other phenylethylamines;
    • Diabetes mellitus Type I, uncontrolled Type II, or controlled Type II managed with insulin; Malignancy/chemotherapy within 2 years prior to Screening;
    • Malignancy >2 yrs may not preclude participation if the malignancy was local and without metastasis or recurrence and, if treated with chemotherapy, had no nervous system complications (e.g basal cell carcinoma);
    • Pheochromocytoma
  • Positive urine test for drugs of abuse (blood for alcohol)
  • Female subject who is pregnant or lactating
  • Poor likelihood of subject's cooperation or compliance
Both
18 Years to 60 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00739908
CX157-200
Yes
CeNeRx BioPharma Inc.
CeNeRx BioPharma Inc.
Not Provided
Study Director: Daniel Burch, MD CeNeRx BioPharma Inc.
CeNeRx BioPharma Inc.
June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP